# 1 Title: FCGR2A-131H/H is under-represented amongst patients with 2 primary immunodeficiencies

- 3
- 4 **Short running title (50 Chars): Role of FCGR variants in patients with PID**
- 5
- 6 Edward W D Flewitt<sup>1</sup>, James E G Charlesworth<sup>2, 3</sup>, Smita Y Patel<sup>1,3</sup>, Chantal E Hargreaves<sup>1</sup>
- 7
- <sup>1</sup> 8 Nuffield Department of Medicine and Oxford NIHR Biomedical Research Centre, University of
- 9 Oxford, Oxford, OX3 9DU, UK.
- <sup>2</sup> Department of Paediatrics, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation
- 11 Trust, Oxford, OX3 9DU
- <sup>3</sup> Clinical Immunology Department, John Radcliffe Hospital, Oxford University Hospitals NHS
- 13 Foundation Trust, Oxford, OX3 9DU
- 14 Corresponding author: Smita Y Patel, email: smita.patel@ndm.ox.ac.uk

15

16 Abbreviations: CMC (chronic mucocutaneous candidiasis), CVID (common variable 17 immunodeficiency disorder), F (phenylalanine), FCGR (Fc gamma receptor), H (histidine), HWE 18 (Hardy-Weinberg equilibrium), I (isoleucine), ITP (immune thrombocytopenia purpura), PCR 19 (polymerase chain reaction), PID (primary immunodeficiencies), R (arginine), SLE (systemic lupus 20 erythematosus), SNP (single nucleotide polymorphism), T (threonine), V (valine)

21

22 Word count: 2978

23 Title heading: Human Immunology

## 24 Abstract



39

40 Keywords: primary immune deficiency; PID; common variable immunodeficiency disorders; CVID;

41 cytopenia; Fc gamma receptors

- 42 Funding information: SYP is funded by the Oxford NIHR Biomedical Research Centre, EWDF was
- 43 funded by the University of Oxford's Final Honours School.
- 44 Conflict of interest statement: The authors have no conflicts of interest to disclose.

## 45 Introduction

46 Fcγ receptors (FcγRs) are glycoproteins, encoded on chromosome 1q23-24, which bind the Fc portion 47 of IgG[1, 2]. There are six human FcγRs found on various immune cells which, when ligated, 48 modulate the immune response[2]. FcγRs vary in structure and function, and are classified according 49 to their affinity for IgG immune complexes. The high-affinity FcγRI (CD64) binding monomeric IgG, 50 and the low-affinity receptors, FcγRIIa (CD32a), FcγRIIb (CD32b), FcγRIIc (CD32c), FcγRIIIa 51 (CD16a) and FcγRIIIb (CD16b)[2-5]. Engagement of the FcγRs results in cellular activation, with the 52 exception of FcγRIIb, which is the sole inhibitory receptor. Immune cell activation is balanced by the 53 relative engagement of the activating and inhibiting low affinity FcγRs, with immune dysregulation 54 and autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis 55 resulting from disrupting this balance[1].

56

57 There are three single nucleotide polymorphisms (SNPs) within the low-affinity receptors widely 58 reported to affect receptor function upon IgG binding[1]. These are located in the genes *FCGR2A*, <sup>59</sup>*FCGR2B*, and *FCGR3A* which encode FcγRIIa, FcγRIIb, and FcγRIIIa, respectively[6-8]. In 60 *FCGR2A*, a histidine (H) to arginine (R) SNP (rs1801274) at amino acid 131 61 (NM\_001136219.3(FCGR2A):c.500A>G (p.His131Arg)), in which the H variant confers higher 62 affinity for IgG than the R variant, particularly IgG2[9]. An isoleucine (I) to threonine (T) SNP 63 (rs1050501) is located at amino acid 232 in *FCGR2B* (NM\_004001.4(FCGR2B):c.695T>C 64 (p.Ile232Thr)), with the T variant inhibiting the receptor associating with lipid rafts in the cell 65 membrane, reducing inhibition of B cell receptor signalling[10, 11]. Additionally, polymorphisms 66 within the promoter region of *FCGR2B* have been linked to altered receptor expression and 67 autoimmunity[12]. In *FCGR3A*, a phenylalanine (F) to valine (V) SNP ( rs39699) at amino acid 158 68 (NM\_001127593.1(FCGR3A):c.526T>G (p.Phe158Val)), increases the receptor's affinity for IgG[6]. 69 Copy number variants affecting this locus have also been described and reported to affect disease 70 susceptibility[10, 13-16].

71

72 These SNPs are associated with an increased risk of developing autoimmune diseases. The high 73 affinity *FCGR2A* 131H variant is associated with childhood-onset immune thrombocytopenic purpura 74 (ITP), rheumatoid arthritis, and Kawasaki disease[17-19]. Similarly, the high affinity *FCGR3A* 158V 75 variant is associated with both childhood- and adult-onset ITP[18, 20]. No clear pathological 76 mechanism has been established, however variants which confer higher affinity for ligand may lead to 77 greater immune cell activation, and thus autoimmunity. The inhibitory FcγRIIb receptor low affinity 78 *FCGR2B* 232T variant has been associated with ITP and SLE[21-23]. In SLE the decreased inhibitory 79 activity alters the germinal centre's control of peripheral tolerance which is proposed to lead to the 80 hyper-activation of the PI3K pathway, leading to the hyper-reactive features[24, 25].

81

82 Primary immunodeficiencies (PIDs) are a heterogeneous group of rare disorders characterised by poor 83 or absent function of at least one immune system component. Common variable immunodeficiency 84 disorders (CVID), a subtype of PID, is characterised by a marked decrease in IgG and at least one of 85 IgM or IgA, poor antibody response to vaccination, and an onset after 2 years of age, in the absence of 86 other causes of immunodeficiency[26, 27]. CVID has an estimated prevalence of 1 in 25,000 and is 87 the most common symptomatic antibody deficiency disorder[28, 29]. The aetiology of CVID is not 88 fully understood[30]. A genome-wide association study, and our whole genome sequencing study, of 89 patients with CVID both concluded that CVID is a polygenic disease[31, 32]. Patients with CVID can 90 be broadly classed as either infections only or complex. All patients experience recurrent infections, 91 particularly sinopulmonary infections, which often results in bronchiectasis[33]. Those with complex 92 CVID develop disease-related complications, including autoimmunity, cytopenias, granulomatous 93 disease and/or malignancy[34, 35]. The reduction but not absence in IgG and the presence of 94 antibody-mediated autoimmune disease complications in some patients, suggest CVID as a disease of 95 quality as well as quantity of antibody response. With the little antibody that is made possibly 96 recognising self-antigen.

97



### 107 Materials and Methods

108 **Subjects:** DNA of 83 patients with PIDs was available for analysis. These patients were attending the 109 Clinical Immunology outpatient department, John Radcliffe Hospital, Oxford, UK at the time of 110 sampling. Whilst the primary focus of this study is CVID patients (n=56), other PID patients (n=27) 111 were included as non-CVID controls. Many of these patients had clinically validated genetic 112 diagnoses as well as disease-related complications such as cytopenias (**Table 1** and Supplementary 113 Table 1). Diagnosis of CVID was made in accordance to the ESID guidelines[37], with patients being 114 classified as infections only in the absence of any other complication. Patients were diagnosed with 115 cytopenia if leukocytes or platelets were below the normal range for more than 6 months outside 116 treatment for infection. The underlying causes of anaemia were further explored if unlikely to be PID-117 related. Pancytopenia was defined as all three lineages (erythrocytes, platelets, and leukocytes) below 118 the normal range for ≥6 months. Other relevant clinical conditions were noted from patient notes. Our 119 in-house control group consisted of 48 anonymous, healthy volunteers from Oxfordshire, UK. All 120 individuals gave informed written consent. Studies were performed according to the Declaration of 121 Helsinki with South Central Research Ethics Committee approval (12/SC/0044) for patient 122 recruitment. Controls were recruited from the University of Oxford's Nuffield Department of 123 Medicine through the Oxford Gastrointestinal Illness Biobank (16/YH/0247).

124 **Control cohorts:** We calculated the Hardy-Weinberg equilibrium (HWE) using a Chi Squared test for 125 all groups compared to previously published genotype frequencies and found that the patient and 126 control group of *FCGR2A* were not within HWE (p = 0.014 and p = 0.003 respectively) (**Table**  127 **2**)[38]. To ensure a fair control group we supplemented our in-house controls with data on the same 128 three SNPs, genotyped by the same methods, in a large previously published cohort, also shown in 129 **Table 2**[39, 40]. All control groups were now within HWE and only the *FCGR2A* patient group was 130 not (p = 0.014). The power, calculated from previously published population allele frequencies, 131 equalled 1.000 for all three receptors[38].

132 **Laboratory analysis:** gDNA samples were isolated from patient peripheral blood mononuclear cell 133 samples using the Monarch Genomic DNA Purification Kit (New England Biolabs, UK) according to

134 manufacturer's instructions. Samples were analysed at three loci for the SNPs 135 NM\_001136219.3(FCGR2A):c.500A>G (p.His167Arg), NM\_004001.4(FCGR2B):c.695T>C 136 (p.Ile232Thr), and NM\_001127593.1(FCGR3A):c.526T>G (p.Phe176Val) using a previously 137 published TaqMan method[41]. Primers, probes, and cycling conditions are shown in Supplementary 138 Table 2. The data was analysed using the BioRad manager software.

139 **Polymerase Chain Reaction (PCR) amplification:** Samples were amplified using the Applied 140 Biosystems 2720 Thermal Cycler (Applied Biosystems, CA, USA). Each reaction well contained: 141 1µL gDNA 5ng/µL, 12.5µL 2X GoTaq G2 Hot Start Green Master Mix (M7422, Promega, UK), 1µL 142 forward primer 10µM (Invitrogen, UK), 1µL reverse primer 10µM (Invitrogen, UK), 1µL de-ionised 143 H2O. Primer design is shown in Supplementary Table 3. Touchdown PCR was used with cycling 144 conditions shown in Supplementary Table 4. Amplification was confirmed by gel electrophoresis.

145 **Gel electrophoresis:** A 1X Tris-Acetate-EDTA buffer gel with 1% agarose was prepared with a 146 0.01% Diamond Nucleic Acid Stain (Promega, UK). PCR samples were diluted 1 in 10 with de-147 ionised H2O; these were mixed with 6X DNA Loading Dye (Thermo Scientific, UK). The samples 148 were run for 2 hours at 110V, the Quick-Load Purple 1kb Plus Ladder (New England Biolabs, UK) 149 was used. Samples were then imaged using the ChemiDoc UV imager (Bio-Rad Laboratories, CA, 150 USA). A single clear band at the correct number of base pairs (*FCGR2A*: 627bp, *FCGR2B*: 751bp, 151 *FCGR3A*: 927bp) was taken as confirmation of amplification.

152 **Sanger sequencing:** Samples were purified using the Monarch PCR & DNA Cleanup Kit (5µg) (New 153 England Biolabs, UK) according to manufacturer's instructions, using 20µL of PCR product and 154 10µL of elution buffer. A NanoDrop 1000 (Thermo Fisher Scientific, MA, USA) full spectrum 155 spectrophotometer was used to determine the concentration of each sample. Samples were diluted 156 with de-ionised H<sub>2</sub>O to a concentration of  $5{\text -}20\frac{n\mu L}$ . The samples were Sanger sequenced at the 157 MRC Weatherall Institute of Molecular Medicine (UK). Primer designs are shown in Supplementary 158 Table 3. Analysis was performed using FinchTV. For seven samples, the Sanger sequence result 159 differed from the TaqMan result. The TaqMan result was used for the *FCGR2A* and *FCGR2B* samples 160 and the Sanger sequencing result in the *FCGR3A* samples per findings of Hargreaves et al.

161 demonstrating superiority of the TaqMan assays for *FCGR2A* and *FCGR2B*, and the Sanger 162 sequencing assay for *FCGR3A*[41]. For *FCGR2B* this is due to the presence of known SNPs at the 163 Sanger sequencing probe binding sites which have been shown to disrupt the Sanger sequencing 164 results and report an over-representation of the *FCGR2B*-232T allele compared to previously 165 published frequencies[10, 41, 42]. One sample for *FCGR3A* was not included in the study due to 166 Sanger sequencing returning an inconclusive result. The decision-making process is shown in 167 Supplementary Figure 1.

- 168 **Statistics:** IBM SPSS Statistics (Version 27) was used to perform Chi Squared tests; R (Version
- 169 4.0.3, pwr package 1.3-0) was used to perform power calculations. Excel (Microsoft Office) was used
- 170 to calculate Hardy-Weinberg equilibrium. For all tests, p<0.05 was considered significant.

## 171 Results

#### 172 *FCGR2A***-131H/H is under-represented amongst PID patients**

173 Altered genotype frequencies of *FCGR2A*-R131H have been found in different patient groups as 174 compared to controls. Specifically, an increased prevalence of the 131H allele is associated with an 175 increased risk of diseases, including Kawasaki disease and ITP[17, 18]. We sought to establish the 176 allele frequency amongst patients with CVID in comparison to patients with other PIDs, in-house 177 immunocompetent controls and a previously published cohort of immunocompetent patients 178 undergoing cancer immunotherapy[40].

179 For *FCGR2A*-131H/R we found a significant difference between genotype distribution in patients 180 with a PID and controls (p=0.019), but no significant difference in allele frequencies (p=0.231) 181 (**Table 3**). This difference was a decrease in the 131H/H genotype and a corresponding increase in the 182 heterozygous 131H/R genotype amongst all PID patients, compared to immunocompetent controls. 183 Subgroup analysis showed that this significant difference in genotype distribution was driven by the 184 mixed non-CVID PID group (p=0.004) but not the CVID cohort (p=0.124) when compared to our 185 control group (**Table 4**).

186 There was a statistically significant difference between the genotype distribution of the mixed non-

187 CVID PID group and the CVID group (p=0.039), with the 131R/R genotype making up 30.2% of

188 CVID patients compared to just 10.7% of non-CVID PID patients (**Table 4**). There was no significant

189 difference in allele frequencies upon any subgroup analysis (**Table 4**).

190 Further subgroup analysis of genotype and allele distribution based upon clinical phenotypes found no 191 significant differences (**Table 5**).

### 192 **In PID patients there was no significant difference in** *FCGR2B***-232I/T and** *FCGR3A***-158F/V**

193 **compared to controls** 

194 Altered genotype frequencies of *FCGR2B*-232I/T and *FCGR3A*-158F/V have been found in patient 195 groups compared with controls. The low affinity 232T variant has been associated with an increased

196 risk of ITP and SLE[21-23]. Whilst the high affinity 158V variant has been shown to be associated 197 with both childhood- and adult-onset ITP[18, 20]. We sought to establish the allele frequency 198 amongst patients with CVID in comparison to patients with other PIDs, in-house immunocompetent 199 controls and a previously published cohort of immunocompetent patients undergoing cancer 200 immunotherapy[40].

- 201 For both *FCGR2B*-232I/T and *FCGR3A*-158F/V we found no significant difference in genotype
- 202 distribution (p=0.260, p=0.659) or allele frequencies (p=0.235, p=0.573) compared to controls (**Table**
- 203 **3**). Subgroup analysis breaking down the PID population into CVID, non-CVID and CMC groups
- 204 also yielded no significance in either genotype distribution or allele carriage (**Table 4**) and neither did
- 205 analysis based upon clinical phenotype (**Table 5**).

## 206 Discussion

207 The clinical significance of low affinity FcγR in disease has been investigated by various groups over 208 the last 20 years[43]. Previous studies in Kawasaki disease and ITP found that the *FCGR2A*-131R/R 209 genotype is linked with increased disease risk[17, 18]. The mechanisms behind this association have 210 not been explored. However, due to the differing affinities between these receptors it leads to 211 variation in the clearing of immune complexes, antigen presentation, and antibody mediated 212 phagocytosis all of which play a role in autoimmune diseases[20]. It is possible that the greater 213 proportion of the high affinity allele could result in an increased clearance of IgG sensitized cells. 214 Thus, leading to an overactivation of the immune system which could cause autoimmune attacks 215 which impair aspects of the immune system, causing a PID to develop.

216 We found no association between *FCGR2A* polymorphisms and CVID incidence rates (p=0.124). 217 Although our data did support an association between *FCGR2A* polymorphism and the presence of 218 any PID compared to control ( $p=0.004$ ). This association was a decrease in the proportion of the high 219 affinity 131H/H receptor within the patient group compared to controls. Whilst this has not been 220 previously explored, the finding was interesting given the opposite previous findings in ITP and 221 Kawasaki's disease[17, 18]. Due to the relatively small non-CVID cohort we were unable to further 222 explore this association, however, this result does imply that the mechanism driving low platelet 223 counts could differ between CVID and non-CVID ITP. Also, given the majority of non-CVID PIDs 224 within our patient cohort had CMC (Supplementary Table 1) there is a possibility that this 225 polymorphism is linked to inhibition of the Th17 and Th1 immune cell pathways which have 226 previously been implicated in CMC progression[44]. To prove such a link would require further 227 research into the area.

228 We found no significant differences between the CVID and PID cohorts and controls in both 229 *FCGR2B* (p=0.260) and *FCGR3A* (p=0.659). This may be due to *FCGR2B* and *FCGR3A* not 230 contributing to pathology in this cohort, or our it could be that our cohort is simply too small to detect 231 an association driven by these variants.

232 We supplemented our controls with data collected from Strefford et al[40]. The patients involved in 233 this study were being treated with either obinutuzumab- or rituximab-chemotherapy for untreated 234 follicular lymphoma and diffuse large B-cell lymphoma in the GALLIUM and GOYA trials[45, 46]. 235 While the cohort are not healthy individuals; the median age of patients in these studies 236 (GALLIUM=59 years, GOYA=62 years) was significantly higher than the typical age of diagnoses 237 for CVID (20-40 years) or other PIDs (median 9.5 years)[47, 48]. It is therefore unlikely that 238 undiagnosed PID cases could be within the reference control cohort. FcγR genetics have never been 239 demonstrated to predispose to cancer, and indeed the genotype frequencies were within expected 240 frequencies for this cohort, suggesting there was no selection pressure as demonstrated amongst 241 autoimmune cohorts. Furthermore, neither cancer is directly linked to the presence of a PID and 242 therefore for our purposes these patients form a suitable control group.

243 When comparing the Sanger sequence traces to the TaqMan data there were occasional discrepancies 244 between the two readouts. For both *FCGR2A* and *FCGR2B* we prioritised the readout from the 245 TaqMan assays as this has been previously validated[41]. For *FCGR3A,* there is copy number 246 variation which can complicate distinguishing FFV and FVV genotypes from FV[13]. Sanger 247 sequencing is less affected, providing the sequence from each allele can be detected, and thus this was 248 prioritised in cases of discrepancy[41].

#### 249 **Study limitations**

250 The small sample size was a limitation of this study, especially within the non-CVID patient cohort, 251 as this limited the analysis which could be performed on the statistically significant difference found 252 at the *FCGR2A* SNP. The number of different diseases present within the non-CVID patients 253 (Supplementary Table 1) is also potentially problematic given that the different genetic make-up of 254 each disease could affect the FcγRs differently.

255 A further limitation of the study is the discrepancies present between our TaqMan and Sanger 256 sequencing results. We are not sure why we had a higher rate of discrepancy than researchers who 257 have previously used the same methodology[40]. However, to mitigate the effect of these

258 discrepancies future work could involve the Sanger sequencing of a larger percentage of samples. 259 Given that in both *FCGR2A* and *FCGR3A* it was the same patient sample which was discordant this 260 could be due to a case of individual genetic variation, rather than a systemic issue. Finally, a repeat of 261 the genotyping using a different set of primers could lead to a set of concordant results. For instance, a 262 nested PCR protocol could lead to increased consistency in results due to its potential for higher 263 sensitivity and specificity[49].

#### 264 **Further work**

265 This work could be expanded upon by increasing patient numbers, particularly the number of non-266 CVID patients, and exploring a wider range of PID related complications. Doing so could allow for a 267 greater insight to the rare *FCGR2B*-232T/T genotype, as well as the rarer complications observed. 268 However, given that PIDs are rare diseases, this would certainly require collaboration with a group(s) 269 from a different geographical area as we were able to access samples from the majority of consenting 270 PID patients who have lived within the John Radcliffe catchment area in the last decade. 271 Alternatively, given the increasing number of PID patients who have undergone whole genome 272 sequencing this could be an avenue for further analysis of the Fc $\gamma$ R SNPs mentioned[32].

273 Further, we did not consider the remaining two low affinity FcγRs: *FCGR2C* and *FCGR3B*. Both 274 genes contain disease-associated SNPs and copy number variations[50]. These differences have been 275 shown in previous studies to play a role in immune diseases such as SLE and ITP and thus may 276 potentially play a role in CVID development given their expression on natural killer cells and 277 neutrophils, something that could be explored in future research[3, 51, 52].

#### 278 **Conclusions**

279 In summary, our results show that there is no significant genetic role of SNPs on the *FCGR2A*, 280 *FCGR2B*, and *FCGR3A* genes in CVID. We have shown that these SNPs both do not affect the risk of 281 developing CVID and are also not implicated in an increased risk of developing any of the most 282 common complications. We found evidence suggesting that *FCGR2A* may play a role in the 283 development of PIDs, but further studies of these FcγR SNPs are needed to confirm this finding.



294

295 Conflict of interest statement: The authors have no conflicts to declare.

# 296 References



It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.12.23296440;](https://doi.org/10.1101/2023.10.12.23296440) this version posted October 13, 2023. The copyright holder for this preprint

349 23 Wu Z, Zhou J, Prsoon P, Wei X, Liu X, Peng B. *Low expression of FCGRIIB in macrophages*  350 *of immune thrombocytopenia-affected individuals*. Int J Hematol. 2012 Nov;96:588-93. 351 24 Xu L, Li G, Wang J *et al. Through an ITIM-independent mechanism the Fc*γ*RIIB blocks B*  352 *cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19*. J 353 Immunol. 2014 Jun 1;192:5179-91. 354 25 Weisenburger T, von Neubeck B, Schneider A *et al. Epistatic Interactions Between Mutations*  355 *of Deoxyribonuclease 1-Like 3 and the Inhibitory Fc Gamma Receptor IIB Result in Very Early and*  356 *Massive Autoantibodies Against Double-Stranded DNA*. Front Immunol. 2018;9:1551. 357 26 Bousfiha A, Moundir A, Tangye SG *et al. The 2022 Update of IUIS Phenotypical*  358 *Classification for Human Inborn Errors of Immunity*. Journal of Clinical Immunology. 2022 359 2022/10/01;42:1508-20. 360 27 Conley ME, Dobbs AK, Farmer DM *et al. Primary B Cell Immunodeficiencies: Comparisons*  361 *and Contrasts*. Annual Review of Immunology. 2009;27:199-227. 362 28 Bonilla FA, Barlan I, Chapel H *et al. International Consensus Document (ICON): Common*  363 *Variable Immunodeficiency Disorders*. The Journal of Allergy and Clinical Immunology: In Practice. 364 2016 2016/01/01/;4:38-59. 365 29 Cunningham-Rundles C, Maglione PJ. *Common variable immunodeficiency*. J Allergy Clin 366 Immunol. 2012 May;129:1425-6.e3. 367 30 de Valles-Ibáñez G, Esteve-Solé A, Piquer M *et al. Evaluating the Genetics of Common*  368 *Variable Immunodeficiency: Monogenetic Model and Beyond*. Front Immunol. 2018;9:636. 369 31 Orange JS, Glessner JT, Resnick E *et al. Genome-wide association identifies diverse causes*  370 *of common variable immunodeficiency*. J Allergy Clin Immunol. 2011 Jun;127:1360-7.e6. 371 32 van Schouwenburg PA, Davenport EE, Kienzler A-K *et al. Application of whole genome and*  372 *RNA sequencing to investigate the genomic landscape of common variable immunodeficiency*  373 *disorders*. Clinical Immunology. 2015 2015/10/01/;160:301-14. 374 33 Ramzi N, Jamee M, Bakhtiyari M *et al. Bronchiectasis in common variable*  375 *immunodeficiency: A systematic review and meta-analysis*. Pediatr Pulmonol. 2020 Feb;55:292-9. 376 34 Cunningham-Rundles C. *The many faces of common variable immunodeficiency*. Hematology 377 Am Soc Hematol Educ Program. 2012;2012:301-5. 378 35 Chapel H, Lucas M, Lee M *et al. Common variable immunodeficiency disorders: division*  379 *into distinct clinical phenotypes*. Blood. 2008 Jul 15;112:277-86. 380 36 Agarwal S, Cunningham-Rundles C. *Autoimmunity in common variable immunodeficiency*. 381 Curr Allergy Asthma Rep. 2009 Sep;9:347-52. 382 37 Edgar D, Ehl S. *ESID Registry-Working definitions for clinical diagnosis of PID, 2014*. 383 Google Scholar.1-33. 384 38 Nagelkerke SQ, Tacke CE, Breunis WB *et al. Extensive Ethnic Variation and Linkage*  385 *Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease*. 386 Front Immunol. 2019;10:185-. 387 39 Chang C. *Statistical tests*. 2020 [cited; Available from: https://www.cog-388 genomics.org/software/stats 389 40 Strefford JC, Nowicka M, Hargreaves CE *et al. Single-nucleotide Fc*γ *receptor*  390 *polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma*. Blood 391 Adv. 2021 Aug 10;5:2935-44. 392 41 Hargreaves CE, Iriyama C, Rose-Zerilli MJJ *et al. Evaluation of High-Throughput Genomic*  393 *Assays for the Fc Gamma Receptor Locus*. PLoS One. 2015;10:e0142379-e. 394 42 Li SS, Gilbert PB, Tomaras GD *et al. FCGR2C polymorphisms associate with HIV-1 vaccine*  395 *protection in RV144 trial*. J Clin Invest. 2014 Sep;124:3879-90. 396 43 Lehrnbecher T, Foster CB, Zhu S *et al. Variant genotypes of the low-affinity Fcgamma*  397 *receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms*  398 *in control and disease populations*. Blood. 1999 Dec 15;94:4220-32. 399 44 Eyerich K, Eyerich S, Hiller J, Behrendt H, Traidl-Hoffmann C. *Chronic mucocutaneous*  400 *candidiasis, from bench to bedside*. Eur J Dermatol. 2010 May-Jun;20:260-5. 401 45 Marcus R, Davies A, Ando K *et al. Obinutuzumab for the First-Line Treatment of Follicular*  402 *Lymphoma*. N Engl J Med. 2017 Oct 5;377:1331-44.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.12.23296440;](https://doi.org/10.1101/2023.10.12.23296440) this version posted October 13, 2023. The copyright holder for this preprint

- 403 46 Vitolo U, Trněný M, Belada D *et al. Obinutuzumab or Rituximab Plus Cyclophosphamide,*
- 404 *Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma*. J 405 Clin Oncol. 2017 Nov 1;35:3529-37.
- 406 47 Herber M, Mertz P, Dieudonné Y *et al. Primary immunodeficiencies and lymphoma: a*  407 *systematic review of literature*. Leuk Lymphoma. 2020 Feb;61:274-84.
- 408 48 Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. *Morbidity and mortality in*  409 *common variable immune deficiency over 4 decades*. Blood. 2012 Feb 16;119:1650-7.
- 410 49 Green MR, Sambrook J. *Nested Polymerase Chain Reaction (PCR)*. Cold Spring Harb Protoc. 411 2019 Feb 1;2019.<br>412 50 Erbe AK,
- 412 50 Erbe AK, Wang W, Gallenberger M, Hank JA, Sondel PM. *Genotyping Single Nucleotide*
- 413 *Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells*. Methods Mol Biol. 2016;1441:43-56.
- 415 51 Kyogoku C, Dijstelbloem HM, Tsuchiya N *et al. Fcgamma receptor gene polymorphisms in*
- 416 *Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic*
- 417 *susceptibility*. Arthritis Rheum. 2002 May;46:1242-54.
- 418 52 Breunis WB, van Mirre E, Bruin M *et al. Copy number variation of the activating FCGR2C*  419 *gene predisposes to idiopathic thrombocytopenic purpura*. Blood. 2008 Feb 1;111:1029-38.

# 420 Tables



421 **Table 1. Clinical characteristics of cohort studied.** †Phenotypic classification for 6 CVID patients was unable to be

422 determined.



423 **Table 2. Genotype distributions and HWE calculations in patients with a PID, in-house control subjects, and total** 

424 **supplemented control groups.** Bold italic values are statistically significant. †There were fewer than 5 individuals within a

425 group so a HWE exact test was performed[39].



426 **Table 3. Genotype distributions and allele frequencies for patients with PIDs and controls.** Bold italic values are

427 statistically significant.

428





### 429 **Table 4. Genotype and allele carriage statistical differences between cohort groups.** Bold italic values are statistically

430 significant.

431



Complex	6(33.3)	9 (50.0)	3(16.7)	.217(3.055)	.327(0.961)
Anaemias	11(45.8)	7(29.2)	6(25.0)	.072(5.249)	.469(0.524)
Organ-Specific	(42.9) 6	(50.0) $7^{\circ}$	1(7.1)	.570(1.125)	.875(0.025)
Autoimmunity					
<b>Bronchiectasis</b>	17(53.1)	10(31.3)	5(15.6)	.524(1.292)	.879(0.023)
Splenomegaly	10(43.5)	8 (34.8)	5(21.7)	.269(2.625)	.469(0.524)
Granulomata	(28.6) 4	9(64.3)	1(7.1)	.089(4.848)	.443 (0.589)
Cytopenias	10(47.6)	(28.6) 6	5(23.8)	.228(2.960)	.564(0.333)

432 **Table 5. Analysis of complications development, broken down by SNP, within the PID cohort.**

# 433 Figure Legends

- 434 **Figure 1. TaqMan genotyping plots with gating strategy shown.** gDNA samples were genotyped
- 435 in triplicate for genes *FCGR2A*, *FCGR2B,* and *FCGR3A*. The reference alleles for each gene are
- 436 shown in orange circles, the alternate allele in blue squares and heterozygotes in green triangles and
- 437 non-template controls as black diamonds. Gates were manually drawn to genotype samples. Samples
- 438 which were not easily gated were confirmed by Sanger sequencing.



**n genotyping plots with gating strategy shown.** gDNA samples were genotyped in triplicate for genes *FCGR2A*, *FCGR2B* and *FCGR3A*. The reference alleles for each gene are shown in orange circles, the alternate allele in blue squares and heterozygotes in green triangles and non-template as black diamonds. Gates were manually drawn to genotype samples. Samples which were not easily gated were confirmed by Sanger sequencing.